Viking Therapeutics (VKTX) Other Accumulated Expenses (2014 - 2026)

Viking Therapeutics has disclosed Other Accumulated Expenses across 13 years of filings, most recently posting $40.5 million for Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 55.6% year-over-year to $40.5 million; the TTM figure through Jun 2026 stood at $40.5 million (up 55.6% YoY), while the FY2025 annual figure was $23.3 million, up 36.05% from the prior year.
• Other Accumulated Expenses came in at $40.5 million for Q2 2026 at Viking Therapeutics, up from $39.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $40.5 million in Q2 2026 to a low of $7.4 million in Q3 2023.
• Average Other Accumulated Expenses over 5 years is $17.9 million, with a median of $13.4 million recorded in 2022.
• Year-over-year, Other Accumulated Expenses sank 58.22% in 2025 and surged 244.17% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $13.1 million in 2022, then slipped by 13.84% to $11.3 million in 2023, then jumped by 51.44% to $17.1 million in 2024, then jumped by 36.05% to $23.3 million in 2025, then soared by 73.9% to $40.5 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $40.5 million in Q2 2026, $39.1 million in Q1 2026, and $23.3 million in Q4 2025.